Tweet #436110703507038208
Novartis compound LDE225 met primary endpoint in pivotal trial for patients with advanced BCC #NMskincancer zite.to/1fyjRLo
Novartis compound LDE225 met primary endpoint in pivotal trial for patients with advanced BCC #NMskincancer zite.to/1fyjRLo